Novartis raises 2026 profit outlook as drug sales offset $1.9 billion impairment

Novartis (NYSE:NVS) raised its 2026 core operating income outlook after Q3 sales growth and margin improvements. Q3 net sales rose 4% to $14.5B, core operating income up 10% to $6B. Impairment of $1.9B for del-desiran led to a 61% drop in reported operating income. Key drugs like Kisqali, Kesimpta, Scemblix, and Leqvio drove growth.

Original reporting
Published Oct 27, 2026, 1:05 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 27, 2026, 1:44 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Novartis raises 2026 profit outlook as drug sales offset $1.9 billion impairment — source image
Decision brief

The 30-second read

$NVSBullishHigh
01

Why it matters

The guidance raise offsets the impairment impact, suggesting resilient core operations.

02

Market read

Guidance upgrade for a major pharma player is likely to move the stock and influence sector sentiment.

03

What to watch

The $1.9 bn impairment and missed trial for del‑desiran may weigh on longer‑term sentiment.

Relevance 8/10Novelty 8/10Timing: today

Background

Novartis reported Q3 results with mixed performance: strong sales growth in key drugs but a large impairment from a failed trial.

Company-level read

Ticker impact

$NVSBullishHigh confidence
Context

Novartis raised its 2026 core operating income outlook, shifting from a projected decline to flat or low single‑digit growth.

Expected impact

likely upside as investors price in improved operating income outlook

Evidence & confidence

The new guidance is a primary disclosure with material financial numbers for a large‑cap pharma company.

Market effects

Other pharma and biotech stocks may see modest support as the sector benefits from a major player’s improved outlook.

European markets could see a lift in healthcare indices.

Global biotech investors may adjust expectations for pipeline valuations.

Counterpoint

If the impairment charge signals deeper pipeline risks, the upgrade could be short‑lived.

Key entities

  • Novartis AG

    Swiss pharmaceutical group, ticker NVS.

Related articles

$LLYMedAI 8/10

Rx Rundown: Ollin Biosciences, AstraZeneca, Isomorphic Labs and more

Eli Lilly, AbbVie, Johnson & Johnson, and others announced major deals and acquisitions in the biopharma sector, totaling billions. AstraZeneca, Roche, and Novo Nordisk received FDA approvals for new treatments. Isomorphic Labs raised $5 billion in private financing. AstraZeneca cut 600 jobs, while Cellectis plans to cut 70% of its workforce.

$NVSMedAI 8/10

Novartis Trims Growth Target at Annual Management Day, Shares Slide

Novartis reduced its mid-term sales growth outlook to 5% annually from 2026-2031, down from a prior 5-6% range. Shares fell 3% on the news. The revision follows patent expirations and clinical trial failures, including a $2.2B writedown. Despite this, Novartis raised peak sales forecasts for three key drugs: Kesimpta, Scemblix, and Leqvio. The company expects growth beyond 2031 from internally developed medicines, with 10 in late-stage development.

$NVSMed

Novartis trims medium-term growth target, shares fall

Novartis reduced its annual sales growth target to 5% through 2031, down from a previous range of 5%-6%. Shares fell 3.3% after the announcement, which came amid patent expirations and clinical trial setbacks. The company expects growth from existing drugs like Kesimpta, Scemblix, and Leqvio, with no large acquisitions planned. Analysts anticipate growth slowing post-2030 due to competition for key drugs.